Ticagrelor recommended by NICE for acute coronary syndromes

Premature discontinuation of antiplatelets in ACS should be avoided | SCIENCE PHOTO LIBRARY
Premature discontinuation of antiplatelets in ACS should be avoided | SCIENCE PHOTO LIBRARY

NICE has recommended ticagrelor (Brilique) in combination with low-dose aspirin for up to 12 months as a treatment option for adults with acute coronary syndromes (ACS), ie, STEMI, NSTEMI or unstable angina.

Ticagrelor inhibits platelet aggregation and thrombus formation by acting as a reversible antagonist of the P2Y12 adenosine diphosphate receptor.

Dosing

Ticagrelor requires a loading dose of 180mg and is subsequently given at a dose of 90mg twice daily for up to 12 months. Patients should also be given a single loading dose of aspirin and continued on an aspirin dose of 75–150mg daily.

Study data

The double-blind, phase 3 PLATO study (n=18,624) compared ticagrelor with clopidogrel, both co-administered with aspirin, over a period of 12 months in patients hospitalised with ACS.

Ticagrelor was significantly more effective than clopidogrel in preventing vascular events in patients with ACS (event rates of 9.8% vs 11.7%; hazard ratio 0.84; 95% CI 0.75–0.95; p<0.001).

There was no significant difference in the rate of major bleeding between the two groups, although more patients taking ticagrelor withdrew from the study because of adverse effects.

NICE — ticagrelor in ACS

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Ticagrelor approved for long-term treatment following MI

Ticagrelor approved for long-term treatment following MI

The antiplatelet treatment Brilique (ticagrelor) can...

NICE recommends apixaban but rejects roflumilast

NICE recommends apixaban but rejects roflumilast

New recommendations from the national body have been...

Ticagrelor: new alternative to clopidogrel

Ticagrelor: new alternative to clopidogrel

Ticagrelor (Brilique) is a new antiplatelet agent offering...

Phase III success for platelet inhibitor

Phase III success for platelet inhibitor

A new antiplatelet drug has outperformed the current...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases